Nurix Therapeutics Inc

Nurix Therapeutics Inc a biopharmaceutical company focuses on the discovery development and commercialization of small molecule therapies for the treatment of cancer and immune disorders The company develops NX2127 an orally available Brutons tyrosine kinase BTK degrader for the treatment of relapsed or refractory Bcell malignancies NX5948 an orally bioavailable BTK degrader for the treatment of relapsed or refractory Bcell malignancies and autoimmune diseases and NX1607 an orally available Casitas Blineage lymphoma protooncogeneB CBLB inhibitor for immunooncology indications It also develops NX0255 a CBLB inhibitor for ex vivo use to enhance adoptive Tcell therapy and DeTIL0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers including ovarian endometrial and cervical cancer The company has a strategic collaboration agreement with Gilead Sciences Inc for cancer and other challenging diseases patients and Sanofi SA The company was formerly known as Nurix Inc and changed its name to Nurix Therapeutics Inc in October 2018 The company was incorporated in 2009 and is headquartered in San Francisco California